Innocrin Pharmaceuticals
Latest round
- Series D
Last raised
- Apr 2015
Total raised
- $28M
Investors
- 6
About Innocrin Pharmaceuticals
Innocrin Pharmaceuticals is a private biotechnology firm focused on developing innovative oral treatments to combat hormone-sensitive cancers, particularly prostate and breast cancer.Innocrin Pharmaceuticals was founded in 2004 in Durham, US, specializing in the development of therapies for hormone-dependent cancers. The company has not undergone significant changes in its business strategy and operates as an independent entity without reported subsidiaries. The firm's founder's details are not available.Innocrin Pharmaceuticals is engaged in the clinical development of novel oral inhibitors targeting the CYP17 lyase enzyme, focusing on conditions such as castration-resistant prostate cancer (CRPC) and advanced breast cancer. Its main product, seviteronel, is a dual-action CYP17 inhibitor and androgen receptor antagonist, distinguished by its ability to selectively inhibit CYP17 lyase without impacting mineralocorticoid or glucocorticoid synthesis. The company is conducting clinical studies in the United States and Europe to assess the efficacy and safety of seviteronel for treating both prostate cancer and estrogen receptor-positive (ER+) as well as triple-negative breast cancer (TNBC).Innocrin Pharmaceuticals' revenue model is founded on its clinical research activities and the forthcoming commercialization of seviteronel and related products. Revenue generation is projected through partnerships with healthcare institutions and direct sales following regulatory approvals. The clinical development phase includes financial transactions related to research contracts, grants, and potential collaborations with larger pharmaceutical companies for distribution and marketing rights.The firm plans to continue focusing on the clinical development of seviteronel, with a strategy aimed at launching the product following successful trials and regulatory approval. Innocrin Pharmaceuticals is targeting expansion into additional European markets and potentially Asia by 2026.00 mn will support the company's ongoing clinical trials and the establishment of partnerships for future commercialization efforts, ensuring a robust infrastructure for launching seviteronel in new markets.
Who invested in Innocrin Pharmaceuticals
6 investors across 1 round
See all investors in Innocrin Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series D
Apr 14, 2015
Amount
$28M
Investors
Questions about Innocrin Pharmaceuticals
Who invested in Innocrin Pharmaceuticals?
Innocrin Pharmaceuticals has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innocrin Pharmaceuticals raised?
Innocrin Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Innocrin Pharmaceuticals last raise money?
Innocrin Pharmaceuticals's most recent round on record is a Series D, in Apr 2015.
What does Innocrin Pharmaceuticals do?
Innocrin Pharmaceuticals is a private biotechnology firm focused on developing innovative oral treatments to combat hormone-sensitive cancers, particularly prostate and breast cancer.
Where is Innocrin Pharmaceuticals headquartered?
Innocrin Pharmaceuticals is headquartered in Durham, US.
Which VCs invest in companies like Innocrin Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Innocrin Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Innocrin Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.